ZURA
NASDAQ · Biotechnology
Zura Bio Ltd
$5.63
-0.15 (-2.60%)
Open$5.80
Previous Close$5.78
Day High$5.82
Day Low$5.55
52W High$7.44
52W Low$1.47
Volume—
Avg Volume877.5K
Market Cap566.81M
P/E Ratio—
EPS$-0.75
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+310.7% upside
Current
$5.63
$5.63
Target
$23.12
$23.12
$15.51
$23.12 avg
$31.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 178.15M | 170.40M | 174.38M |
| Net Income | 4.79M | 4.86M | 5.73M |
| Profit Margin | 2.7% | 2.9% | 3.3% |
| EBITDA | 8.96M | 8.92M | 9.38M |
| Free Cash Flow | 5.34M | 5.40M | 5.82M |
| Rev Growth | +24.5% | +6.4% | +20.2% |
| Debt/Equity | 0.26 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |